PRostate Olaparib Real World Evidence Study
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Registration Number
- NCT06031805
- Lead Sponsor
- AstraZeneca
- Brief Summary
This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 300
Inclusion Criteria
- Adult male patients (≥ 18 years old)
- With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
- Who have been informed and are not opposed to this data collection
Exclusion Criteria
- Patients opposed to the collection of their data
- Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to treatment discontinuation (TTD) Up to 36 months from olaparib initiation TTD is defined as the time from the first day of olaparib treatment to the day that olaparib stopped for whatever reason or the date of death due to any cause, whichever comes first
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇫🇷Vantoux, France